Current Treatment Options Are Limited Leaving Many Patients Unhappy


  • Patients are refractory or unsatisfied with medical management1
  • FESS patients can experience uncontrolled rhinitis2
  • Allergy immunotherapy patients can experience continued drainage
  • Multiple devices may be needed to treat all areas
  • Septoplasty and/or turbinate reduction may only address some symptoms
  • Other ablative technologies have varied patient responses

Comprehensive Treatment with RhinAer

  • Disrupts posterior nasal nerve (PNN) that triggers rhinitis3
  • Treats full length of turbinate
  • Incisionless and can be done under local anesthesia
Aerin Medical RhinAer Stylus treatment
Aerin Medical Aerin System RhinAer Stylus

Clinically Proven Durable Results and High Patient Satisfaction

Significant Improvement Shown in Prospective, Multicenter Study 3

  • Both allergic and nonallergic patients
  • ALL four TNSS symptoms, post-nasal drip, and chronic cough.
  • Patients averaged improvement across all quality of life measures

*100% Responder rate for 1 point or more improvement in rTNSS; If using a 30% reduction in rTNSS from baseline, responder rate is 81%.

Which Patients Can Benefit Most From RhinAer?

  • Patients with moderate to severe chronic rhinorrhea, post-nasal drip, congestion and/or chronic clearing of the throat
  • Allergy immunotherapy patients with continued drainage
  • Nonallergic chronic rhinitis patients
  • Post-FESS patients with uncontrolled rhinitis

Ready to Adopt RhinAer Into Your Practice?

RhinAer fits seamlessly into the office or OR environment. Many payers have coverage policies in place for the treatment of nasal airway obstruction or chronic rhinitis. To learn more, contact Aerin Medical at (833)-484-8237

1 Data on file. Aerin Medical Quantitative Market Research.
2 van der Veen J, Seys SF, Timmermans M, Levie P, Jorissen M, Fokkens WJ, et al. Real-life study showing uncontrolled rhinosinusutus after sinus surgery in ateritary referral centre. Allergy. 2017;72(2):282-290.
3 RhinAer Stylus. Prospective, Non-randomized, Multi-Center Clinical Study. 50 patients. Endpoint from baseline to 52 weeks, Patient reported rTNSS score. Aerin Medical TR898.
4 100% Responder rate for 1 point or more improvement in rTNSS; If using a 30% reduction in rTNSS from baseline, responder rate is 81%. The patient who did not report at 52 weeks; reported as a responder at 26 weeks

WEB948-07.B